RxDoctor Payments Data

Kathryn Ryan, DO

Family Medicine · Saxonburg, PANPI 1689681587

Payments from drug & device makers

$374in general payments, 2019–2025

Across 23 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$118
  • Lilly USA, LLC$91
  • AbbVie$41
  • Merz North America, Inc.$33
  • Sumitomo Pharma America, Inc.$23
  • Biohaven Pharmaceutical Holding Company Ltd.$22
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$374 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$66,517
Medicare patients
152
Services billed
1,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide62$79,335
ProliaDenosumab38$65,213
JardianceEmpagliflozin53$61,983
EliquisApixaban50$55,112
JanuviaSitagliptin Phosphate33$53,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$33,085
FarxigaDapagliflozin Propanediol19$28,633
TrulicityDulaglutide23$23,870
Breo ElliptaFluticasone/Vilanterol44$21,403
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$18,128
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$14,430
OzempicSemaglutide14$12,778
Incruse ElliptaUmeclidinium Bromide20$10,798
MyrbetriqMirabegron16$8,609
Levothyroxine Sodium513$4,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$91$103,20685 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$118$83,413116 claims
Novo NordiskOzempic$14$12,77814 claims
AbbVieSynthroid$41$4,113113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Saxonburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →